* Under the asset purchase agreement, Gesynta Pharma AB acquires the assets relating to the OX-MPI program and will progress the candidate drug into proof-of-concept clinical trials

* Under the terms of the agreement Orexo will receive a tiered double digit share of the future revenues that Gesynta Pharma AB generates from the OX-MPI project Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)